Video
Dr. Joyce on financial toxicity and advanced prostate cancer treatments
Author(s):
“We really need to be thoughtful about how our treatment recommendations may induce financial toxicity in patients with advanced prostate cancer,” says Daniel D. Joyce, MD.
Video Player is loading.
In this video, Daniel D. Joyce, MD, discusses the take-home message from the recent Journal of Urology study, “Out-of-Pocket Cost Burden Associated With Contemporary Management of Advanced Prostate Cancer Among Commercially Insured Patients,” for which he served as a study author. Joyce is a urologic oncology fellow at Mayo Clinic, Rochester, Minnesota.
Related Videos
Ekene Enemchukwu, MD, on underutilization of vaginal estrogen for GSM
Sima Porten, MD, on gene-environment interactions in bladder cancer development
Naeem Bhojani, MD, expands on key findings from WATER III trial
Hailey Frye discusses improvement of pain management for nephrolithiasis
Ekene Enemchukwu, MD, on trends in vaginal estrogen use for GSM
How rBCG EAP could open up access for Anktiva in bladder cancer
Betty Wang, MD, recaps 3 key urologic cancer studies from EAU 2025
Neeraj Agarwal, MD, on the safety profile of talazoparib/enzalutamide in mCRPC
Anna Myers, CNP, discusses her approach to preventing UTIs
Joshua J. Meeks, MD, PhD, discusses the impact of neoadjuvant durvalumab approval in MIBC
Related Content
